Sandoz Says Feds Misclassified Generics As 'Innovator Drugs'
IP Law 360
APRIL 11, 2024
sued the Centers for Medicare & Medicaid Services in Washington, D.C., federal court on Wednesday, alleging the agency ignored the company's objection to classifying two of its generics as "innovator drugs," which could impact Sandoz's rebate obligations under Medicaid. Pharmaceutical company Sandoz Inc.
Let's personalize your content